Cosmos Health Inc. (NASDAQ:COSM) reported that sales through its United States direct-to-consumer channel exceeded $92,000 on October 11, 2026. The company also recorded $902,000 in sales over the past 30 days and said average daily sales surpassed $60,000 during the past 10 days.
The reported figures relate to products sold through Cosmos Health’s branded online stores in the United States. The offering includes the 18 Series nutraceuticals, the NOOR brand and skincare products, which are available through individual purchases and subscriptions.
Sales over the trailing 30-day period were $902,000, representing approximately $30,000 per day. Over the past 10 days, average daily sales exceeded $60,000, which the company described as double the 30-day average.
The October 11 result was described as the company’s highest single-day total to date, with sales of more than $92,000.
Cosmos Health said that maintaining the more than $60,000 average daily rate for a full year would correspond to approximately $21.9 million in annualised sales. This figure is conditional on the recent pace continuing.
The company had previously projected annual revenue of over $23 million for its United States products within the next 12 to 18 months. Cosmos Health said the current 10-day pace approaches that projection.
Cosmos Health said its direct-to-consumer model provides a direct relationship with customers and visibility into purchasing behaviour. According to the company, those insights can inform product development and marketing, while the channel also provides greater control over pricing, presentation and the customer experience.
The company said targeted marketing has supported building brand awareness alongside the reported sales acceleration. Chief Executive Officer Greg Siokas said Cosmos Health is assessing whether to apply the model to additional brands in its portfolio and to further markets.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group. It owns pharmaceutical and nutraceutical brands and, through Cana Laboratories S.A., manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices within the European Union.
The company also distributes pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, operates in telehealth through ZipDoctor, Inc., and conducts research and development related to health disorders, nutraceuticals, extracts, generics and over-the-counter products.
Cosmos Health said statements concerning annualised sales, revenue projections and possible expansion of the model are forward-looking and subject to risks and uncertainties. The company cautioned that actual results may differ materially from its expectations because of events outside its control, third-party actions, unknown risks and potentially inaccurate assumptions.
The risks identified by the company include its ability to raise financing, digital asset strategies, the effects of the war in Ukraine and ongoing conflicts in the Middle East and other regions, product development and commercialisation, regulatory clearance, potential asset-backed or tokenised financing, production and revenue timing, gross margins, capital investment, interest rates, foreign exchange rates, inflation and deflation, debt issuance, investigations and litigation, international operations, insurance coverage, accounting charges, tax and other legal or regulatory changes. The company also said further risks may be described in its filings with the Securities and Exchange Commission.
Cosmos Health announced that United States direct-to-consumer sales exceeded $92,000 on October 11, 2026, its highest single day to date. The Company also reported $902,000 in sales over the past 30 days and average daily sales of more than $60,000 over the past 10 days.
Cosmos Health made the announcement on October 13, 2026. The record daily figure relates to October 11, 2026, while the other reported figures cover the trailing 30-day and past 10-day periods.
Cosmos Health reported $902,000 in United States direct-to-consumer sales over the past 30 days. The Company described this as approximately $30,000 per day over that period.
Cosmos Health reported more than $92,000 in United States direct-to-consumer sales on October 11, 2026. The Company said this was its highest single day to date.
Cosmos Health said average daily sales exceeded $60,000 over the past 10 days, double the approximately $30,000 daily average over the trailing 30 days. The figures relate to sales through the Company's United States direct-to-consumer channel.
The figures cover products sold through Cosmos Health's own branded online stores in the United States, including the 18 Series nutraceuticals, the NOOR brand and skincare products. The products are sold both as individual purchases and through subscriptions.
Cosmos Health said brand awareness has continued to build, supported by targeted marketing, and that this has accompanied an acceleration in sales. CEO Greg Siokas also said the Company is reaching consumers directly and learning what they buy and what brings them back.
Cosmos Health said that sustaining the more than $60,000 average daily sales rate over a full year would correspond to approximately $21.9 million in annualised sales. This is conditional on the rate being sustained and is not presented as a completed result.
Cosmos Health said it had previously projected annual revenue of over $23 million for its United States products within the next 12 to 18 months. The Company said the current 10-day pace already approaches that level.
Cosmos Health said direct-to-consumer sales carry attractive margins and provide a direct relationship with the end customer, as well as visibility over purchasing behaviour that can inform product development and marketing. The Company also said the channel gives it greater control over pricing, presentation and the customer experience.
Cosmos Health is evaluating opportunities to extend the model to additional brands within its portfolio and to further markets. CEO Greg Siokas said the United States is being used as a testing ground for learning about product conversion, customer behaviour and repeat purchases.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group with proprietary pharmaceutical and nutraceutical brands. Through subsidiaries, it manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices within the European Union, distributes pharmaceuticals and parapharmaceuticals in Greece and the UK, operates in telehealth through ZipDoctor, Inc., and conducts research and development activities.
Cosmos Health identifies its shares as trading on NASDAQ under the ticker symbol COSM, written in the source as NASDAQ:COSM and, in the company description, as NASDAQ: COSM.
Cosmos Health said its forward-looking statements involve risks and uncertainties, including its ability to raise sufficient financing, develop and commercialise proprietary products and technologies, operate in international markets and manage legal, regulatory and economic changes. The Company also said actual results may differ materially because of events outside its control, third-party actions, unknown risks and potentially inaccurate assumptions.